<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Granulocyte transfusion's (GT) efficacy among adult severe neutropenic <z:hpo ids='HP_0100806'>sepsis</z:hpo> (SNS) patients remains uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed GT's efficacy and its determinants among SNS patients in an adult haematology unit </plain></SENT>
<SENT sid="2" pm="."><plain>The feasibility and safety of granulocyte donation (GD) and determinants of granulocyte yield were also evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Retrospective analysis of granulocyte donors and recipients from March 2008 to October 2009 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Donors: Sixty GDs with a median WBC yield (WBCY) of 65·49 (31·30-131·72) × 10(9) were collected from 48 donors (9 repeat donors) using hydroxyethyl <z:chebi fb="99" ids="28017">starch</z:chebi> and intermittent flow centrifugation aphaeresis after receiving 8 mg <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> and 300 mcg granulocyte colony-stimulating factor, with no serious adverse reactions (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAR</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Six donations were urgently collected &lt;3 h after pre-medication, the median WBCY of which was not significantly different from donations collected &gt;12 h after pre-medication [59·18 (45·68-62·90) × 10(9) vs 67·45 (31·30-131·72) × 10(9) , P = 0·140] </plain></SENT>
<SENT sid="6" pm="."><plain>Only pre-GD absolute neutrophil count (ANC) correlated with WBCY </plain></SENT>
<SENT sid="7" pm="."><plain>Patients: Fifteen patients (12 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemias</z:mpath>, 1 severe AA, 1 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and 1 <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) received median 3 (2-9) ABO/RhD-matched GTs over 2-24 (median 7) days at 3-61 (median 28) days from severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (SN) <z:hpo ids='HP_0003674'>onset</z:hpo> without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAR</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>They received intensive chemotherapies (N = 9), allogeneic transplant (N = 3), autologous stem cell rescue (N = 1) or <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> (N = 2) </plain></SENT>
<SENT sid="9" pm="."><plain>Fourteen had <z:mp ids='MP_0001794'>bacterial</z:mp> (N = 1) <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">infections, fungal</z:e> (N = 3) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> or both (N = 10) and one had severe <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e>; 63·6 and 30·8% of <z:mp ids='MP_0001794'>bacterial</z:mp> and <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> responded, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Median ANC increase (ANC(increase) ) was 1·26 (0-9·25) × 10(9) at 5-20 (median 11) h post-GT </plain></SENT>
<SENT sid="11" pm="."><plain>On multivariate analysis, each patient's median ANC(increase) only significantly correlated positively with median WBC dose/kg (P = 0·013) </plain></SENT>
<SENT sid="12" pm="."><plain>Five (33·3%) patients survived to discharge; the rest had <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>-related mortality (IRM) </plain></SENT>
<SENT sid="13" pm="."><plain>IRM was significantly associated with inotropic requirement (P = 0·004), ventilatory requirement (P = 0·017) and persistent SN (P = 0·007) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: GD is safe and feasible with good WBCY obtainable using our protocol </plain></SENT>
<SENT sid="15" pm="."><plain>The effect of shortening pre-medication interval on WBCY which may prevent delay in initiating GT is worth evaluating </plain></SENT>
<SENT sid="16" pm="."><plain>GT most likely benefits SNS patients with prospects of neutrophil recovery before haemodynamic deterioration </plain></SENT>
<SENT sid="17" pm="."><plain>Large randomised trials investigating the role and timing of GT among such patients are required </plain></SENT>
</text></document>